Align Technology, Inc. $ALGN Shares Bought by Navera Investment Management Ltd.

Navera Investment Management Ltd. lifted its stake in shares of Align Technology, Inc. (NASDAQ:ALGN) by 3.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 787,559 shares of the medical equipment provider’s stock after purchasing an additional 23,080 shares during the quarter. Align Technology comprises 2.7% of Navera Investment Management Ltd.’s investment portfolio, making the stock its 18th biggest position. Navera Investment Management Ltd.’s holdings in Align Technology were worth $149,126,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ALGN. Ninety One UK Ltd boosted its holdings in shares of Align Technology by 58.7% during the 1st quarter. Ninety One UK Ltd now owns 1,937,555 shares of the medical equipment provider’s stock worth $307,800,000 after purchasing an additional 716,954 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Align Technology by 510.3% during the 1st quarter. Federated Hermes Inc. now owns 707,514 shares of the medical equipment provider’s stock worth $112,396,000 after purchasing an additional 591,588 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Align Technology by 4,217.3% during the 1st quarter. Mackenzie Financial Corp now owns 426,205 shares of the medical equipment provider’s stock worth $67,707,000 after purchasing an additional 416,333 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Align Technology by 104.2% during the 1st quarter. AQR Capital Management LLC now owns 404,310 shares of the medical equipment provider’s stock worth $63,133,000 after purchasing an additional 206,308 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Align Technology by 32.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock worth $132,221,000 after purchasing an additional 202,616 shares during the last quarter. 88.43% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Align Technology

In other news, CEO Joseph M. Hogan bought 7,576 shares of the business’s stock in a transaction on Friday, August 1st. The shares were bought at an average price of $131.49 per share, with a total value of $996,168.24. Following the completion of the transaction, the chief executive officer directly owned 184,945 shares in the company, valued at $24,318,418.05. This trade represents a 4.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.66% of the stock is currently owned by insiders.

Align Technology Stock Down 0.8%

Shares of NASDAQ ALGN opened at $130.47 on Wednesday. The firm has a market cap of $9.46 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.48 and a beta of 1.70. Align Technology, Inc. has a 52-week low of $122.00 and a 52-week high of $246.19. The business’s 50 day moving average is $137.18 and its two-hundred day moving average is $165.19.

Align Technology (NASDAQ:ALGN) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.41 EPS. Align Technology has set its Q3 2025 guidance at EPS. Analysts anticipate that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology announced that its board has authorized a share repurchase program on Tuesday, August 5th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

ALGN has been the topic of several recent research reports. Weiss Ratings restated a “hold (c-)” rating on shares of Align Technology in a report on Saturday, September 27th. Stifel Nicolaus decreased their price objective on Align Technology from $275.00 to $200.00 and set a “buy” rating on the stock in a report on Thursday, July 31st. Mizuho set a $210.00 price objective on Align Technology in a report on Thursday, July 31st. Morgan Stanley reiterated an “equal weight” rating and issued a $154.00 price objective (down from $249.00) on shares of Align Technology in a report on Thursday, July 31st. Finally, Evercore ISI upped their price objective on Align Technology from $200.00 to $220.00 and gave the company an “outperform” rating in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $215.00.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.